Organization | Favrille

Favrille Report issue

For profit Phase 2 Phase 3

Founded: San Diego California United States (2000)

Status: Left NME R&D (2008)

Organization Overview

First Clinical Trial

2001

NCT00036426

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2006

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (8)

autologous immunoglobulin idiotype-klh conjugate vaccine (4 trials)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

favld (2 trials)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (3 trials)

sargramostim (leukine) (4 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (1)

id-klh vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 9